Oral Transition from Unasyn and Doxycycline for Skin Infection
Transition to oral amoxicillin-clavulanate 875/125 mg twice daily, which directly replaces the ampicillin-sulbactam (Unasyn) component while maintaining coverage against the same spectrum of pathogens. Continue doxycycline 100 mg twice daily orally if MRSA coverage remains necessary 1.
Rationale for Amoxicillin-Clavulanate
The IDSA guidelines explicitly identify amoxicillin-clavulanate as the oral equivalent of IV ampicillin-sulbactam for skin and soft tissue infections 1. Both agents provide:
- Staphylococcus aureus (methicillin-susceptible) coverage
- Streptococcal species coverage
- Anaerobic bacteria coverage
- Gram-negative organisms (though some may be resistant)
The transition maintains the same antimicrobial spectrum you established with IV therapy, ensuring continuity of appropriate coverage 1.
Addressing the Doxycycline Component
If MRSA Coverage is Required:
Continue doxycycline 100 mg PO twice daily alongside amoxicillin-clavulanate 1. The guidelines list doxycycline as an acceptable oral agent for MRSA skin infections, though it is bacteriostatic with limited recent clinical experience 1.
If MRSA Coverage is NOT Required:
Discontinue doxycycline and use amoxicillin-clavulanate monotherapy. The combination of ampicillin-sulbactam plus doxycycline suggests empiric coverage for possible MRSA; if cultures are negative for MRSA or clinical suspicion is low, monotherapy suffices 1.
Alternative Oral Regimens
If amoxicillin-clavulanate is contraindicated (e.g., severe penicillin allergy):
For Non-MRSA Infections:
- Cephalexin 500 mg four times daily (avoid if immediate-type penicillin hypersensitivity) 1
- Clindamycin 300-450 mg four times daily (covers staphylococci, streptococci, and anaerobes but misses some gram-negatives) 1
For MRSA Coverage:
- Doxycycline 100 mg twice daily as monotherapy 1
- Trimethoprim-sulfamethoxazole 1-2 double-strength tablets twice daily (bactericidal but poorly documented efficacy) 1
- Clindamycin 300-450 mg four times daily (risk of inducible resistance in MRSA) 1
Critical Transition Criteria
Based on the Unasyn drug label and pediatric SSTI trial data, transition to oral therapy when 2:
- Minimum 72 hours of IV therapy completed
- No documented fever for 24 hours
- Improvement or resolution of infection signs/symptoms
These criteria ensure adequate initial source control and clinical stability before oral step-down 2.
Duration of Therapy
Total antibiotic course should not routinely exceed 14 days for uncomplicated skin infections 2. Count the days of IV therapy toward this total duration. Most patients in clinical trials received combined IV-then-oral courses within this timeframe 2.
Important Caveats
Amoxicillin-clavulanate does NOT cover MRSA 1. If MRSA is documented or highly suspected, you must add or substitute an MRSA-active agent.
Doxycycline alone has limited data for streptococcal infections, as some streptococci are resistant 1, 3. Recent data suggests doxycycline monotherapy may be reasonable for presumed streptococcal infections in areas with low tetracycline resistance, but this is not standard practice 3.
Avoid doxycycline in pregnancy and children <8 years due to tooth discoloration risk 1.
The combination regimen you're transitioning from (Unasyn + doxycycline) suggests either polymicrobial infection or empiric MRSA coverage. Review culture data to determine if dual oral therapy is truly necessary or if monotherapy with amoxicillin-clavulanate suffices.